Aprea Therapeutics, Inc. (APRE)
- Previous Close
5.32 - Open
5.37 - Bid --
- Ask --
- Day's Range
5.06 - 5.37 - 52 Week Range
2.78 - 8.85 - Volume
5,646 - Avg. Volume
33,480 - Market Cap (intraday)
27.532M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.95 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.67
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
www.aprea.comRecent News: APRE
Performance Overview: APRE
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APRE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APRE
Valuation Measures
Market Cap
29.16M
Enterprise Value
373.61k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.63%
Return on Equity (ttm)
-63.19%
Revenue (ttm)
583.23k
Net Income Avi to Common (ttm)
-14.29M
Diluted EPS (ttm)
-3.95
Balance Sheet and Cash Flow
Total Cash (mrq)
21.61M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.67M